U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Nadravaleucel

MORE DETAILS

S2RRP2SH5H

structurally diverse
Status:
Investigational
Source:
INN:12339
Source URL:
https://ginas.ncats.nih.gov/ginas/app/substance/S2RRP2SH5H
Class:
STRUCTURALLY DIVERSE

Omidubicel

MORE DETAILS

ET4JC4S66E

structurally diverse
Status:
Possibly Marketed Outside US
Source:
BLA125738
(2023)
Source URL:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979803c9-956c-42e7-9d75-c37cc4e90632
First approved in 2023
Source:
BLA125738
Source URL:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979803c9-956c-42e7-9d75-c37cc4e90632
Class:
STRUCTURALLY DIVERSE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966